Desmopressin
Ddavp, Desmopressin (desmopressin) is a protein pharmaceutical. Desmopressin was first approved as Ddavp on 1982-01-01. It is used to treat enuresis, hemorrhage, neurogenic diabetes insipidus, thrombocytopenia, and von willebrand diseases in the USA. It is known to target vasopressin V1b receptor, vasopressin V2 receptor, vasopressin V1a receptor, and oxytocin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Ddavp, Desmopressin (discontinued: Concentraid, Ddavp, Desmopressin, Minirin, Nocdurna, Noctiva, Stimate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Desmopressin acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DDAVP | Ferring Pharmaceuticals | N-018938 RX | 1984-03-30 | 1 products, RLD, RS |
| DDAVP | Ferring Pharmaceuticals | N-019955 RX | 1995-09-06 | 2 products, RLD, RS |
Show 10 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ddavp | New Drug Application | 2022-09-28 |
| desmopressin acetate | ANDA | 2024-12-30 |
| nocdurna | New Drug Application | 2023-10-19 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
HCPCS
Code | Description |
|---|---|
| J2597 | Injection, desmopressin acetate, per 1 mcg |
Clinical
Clinical Trials
119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nocturia | D053158 | — | R35.1 | — | 8 | 16 | 2 | 9 | 33 |
| Nocturnal enuresis | D053206 | — | N39.44 | — | — | 3 | 11 | 11 | 25 |
| Enuresis | D004775 | — | R32 | — | — | 3 | 11 | 11 | 25 |
| Urinary incontinence | D014549 | HP_0000020 | R32 | — | — | 3 | 10 | 10 | 23 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 4 | 1 | 4 | 3 | 13 |
| Polyuria | D011141 | HP_0000103 | R35 | — | 1 | 3 | 4 | 2 | 10 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | 1 | — | 2 | 4 | 8 |
| Von willebrand diseases | D014842 | EFO_0003910 | D68.0 | — | 2 | — | 1 | 3 | 6 |
| Diabetes insipidus | D003919 | — | E23.2 | — | — | 1 | 1 | 4 | 6 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | — | — | — | 1 | 2 | 3 |
Show 14 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia | D007010 | HP_0002902 | E87.1 | — | 1 | 2 | — | 2 | 4 |
| Inappropriate adh syndrome | D007177 | EFO_1000982 | E22.2 | — | 1 | 1 | — | 1 | 2 |
| Renal colic | D056844 | EFO_1001412 | N23 | — | — | 1 | — | 1 | 2 |
| Colic | D003085 | HP_0011848 | R10.83 | — | — | 1 | — | 1 | 2 |
| Neurogenic diabetes insipidus | D020790 | HP_0000863 | — | — | — | 1 | — | 1 | 2 |
| Leptospirosis | D007922 | EFO_0007344 | A27 | — | 1 | 1 | — | — | 1 |
| Weil disease | D014895 | — | A27.0 | — | 1 | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | 1 | — | — | 1 |
| Sleep apnea syndromes | D012891 | HP_0010535 | G47.3 | — | — | 1 | — | — | 1 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 1 | — | — | — | 2 |
| Cerebral hemorrhage | D002543 | — | — | — | 1 | — | — | — | 1 |
| Thrombotic thrombocytopenic purpura | D011697 | — | M31.19 | — | 1 | — | — | — | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | — | — | — | 1 |
| Type 2 von willebrand disease | D056728 | Orphanet_166081 | D68.02 | — | 1 | — | — | — | 1 |
| Shock | D012769 | — | R57.1 | — | 1 | — | — | — | 1 |
| Ecchymosis | D004438 | HP_0000978 | — | — | 1 | — | — | — | 1 |
| Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | — | 1 | — | — | — | 1 |
| Colorectal neoplasms | D015179 | — | — | — | 1 | — | — | — | 1 |
| Gastrointestinal hemorrhage | D006471 | HP_0002239 | K92.2 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | — | 1 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | 1 | — | — | — | — | 1 |
| Tachycardia | D013610 | HP_0001649 | R00.0 | 1 | — | — | — | — | 1 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
| Thrombosis | D013927 | — | — | 1 | — | — | — | — | 1 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | 1 | — | — | — | — | 1 |
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | 1 | — | — | — | — | 1 |
| Arteriosclerosis | D001161 | EFO_0009086 | I70 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood platelet disorders | D001791 | — | — | — | — | — | — | 2 | 2 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Craniocerebral trauma | D006259 | — | S00 | — | — | — | — | 1 | 1 |
| Hemodilution | D006438 | — | — | — | — | — | — | 1 | 1 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | — | — | — | 1 | 1 |
| Menorrhagia | D008595 | EFO_0003945 | N92.0 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Water-electrolyte imbalance | D014883 | — | — | — | — | — | — | 1 | 1 |
| Hypernatremia | D006955 | HP_0003228 | E87.0 | — | — | — | — | 1 | 1 |
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Desmopressin |
| INN | desmopressin |
| Description | Desmopressin is a synthetic analogue of vasopressin in which 3-mercaptopropionic acid replaces the cysteine residue at position 1 and D-arginine replaces the residue at position 8. An antidiuretic, it increases urine concentration and decreases urine production, and is used (usually as the trihydrate of the acetic acid salt) to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions. It is also used in the diagnosis and treatment of cranial diabetes insipidus and in tests of renal function. It has a role as a vasopressin receptor agonist, a renal agent and a diagnostic agent. |
| Classification | Protein |
| Drug class | vasoconstrictors (vasopressin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 16679-58-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1429 |
| ChEBI ID | 4450 |
| PubChem CID | 5311065 |
| DrugBank | DB00035 |
| UNII ID | ENR1LLB0FP (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AVPR1B
AVPR1B
AVPR2
AVPR2
AVPR1A
AVPR1A
OXTR
OXTR
Organism
Homo sapiens
Gene name
AVPR1B
Gene synonyms
AVPR3, VPR3
NCBI Gene ID
Protein name
vasopressin V1b receptor
Protein synonyms
Antidiuretic hormone receptor 1b, arginine vasopressin receptor 3, AVPR V1b, AVPR V3, pituitary vasopressin receptor 3, V1B receptor, Vasopressin V3 receptor
Uniprot ID
Mouse ortholog
Avpr1b (26361)
vasopressin V1b receptor (Q9WU02)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Noctiva – Avadel Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Desmopressin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,534 documents
View more details
Safety
Black-box Warning
Black-box warning for: Ddavp, Nocdurna
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,124 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use